Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vir BiotechnologyMEX:VIR 52 PS Ratio is 5.16 as of Aug. 19, 2026, which is 78% below its 10-year median of 23.12. GuruFocus rates MEX:VIR with a GF Score™ of 52/100 and a GF Value™ of MXN764.28. The stock has 5 warning signs investors should review. Among 931 Biotechnology companies, Vir Biotechnology ranks better than 67.35% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vir Biotechnology's share price is MXN170.00.
Vir Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN32.92. Hence, Vir Biotechnology's PS Ratio for today is 5.16.
Good Sign:
Vir Biotechnology Inc stock PS Ratio (=5.02) is close to 2-year low of 4.62.
The historical rank and industry rank for Vir Biotechnology's PS Ratio or its related term are showing as below:
MEX:VIR'
s PS Ratio Range Over the Past 10 Years
Min: 1.09 Med: 23.12 Max: 7750
Current: 5.02
During the past 9 years, Vir Biotechnology's highest PS Ratio was 7750.00. The lowest was 1.09. And the median was 23.12.
MEX:VIR's PS Ratio is ranked better than 67.35% of 931
companies
in the Biotechnology industry
Industry Median: 9.45
vs MEX:VIR: 5.02
Vir Biotechnology Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Vir Biotechnology was 1701.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -65.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -31.20% per year.
During the past 9 years, Vir Biotechnology's highest 3-Year average Revenue per Share Growth Rate was 867.40% per year. The lowest was -65.50% per year. And the median was 268.15% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Vir Biotechnology PS Ratio Related Terms
Vir Biotechnology PS Ratio Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vir Biotechnology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Vir Biotechnology's Share Price of today is MXN170.00. Vir Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN32.92.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Vir Biotechnology (MEX:VIR) has a PS Ratio of 5.16 as of Aug. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vir Biotechnology and its competitors. This is 78% below median its historical median of 23.12. Over the past decade, Vir Biotechnology's PS Ratio has ranged from 1.09 to 7,750.00. According to the industry distribution chart, Vir Biotechnology ranks #304 out of 931 companies in the Biotechnology industry, placing it in the top 32.7%.
Is Vir Biotechnology's PS Ratio too high?
Vir Biotechnology's current PS Ratio of 5.16 is 78% below median its 10-year median of 23.12. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 7,750.00. The Biotechnology industry median PS Ratio is 9.45. Vir Biotechnology's value of 5.16 is 45.4% below this industry median. Based on the distribution chart, Vir Biotechnology ranks #304 out of 931 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's PS Ratio compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #304 out of 931 companies for PS Ratio. This puts Vir Biotechnology in the upper half of its industry. The industry median PS Ratio is 9.45. Vir Biotechnology's value of 5.16 is 45.4% below this benchmark. Historically, Vir Biotechnology's own PS Ratio has ranged from 1.09 to 7,750.00 over the past decade. While the company's 10-year median is 23.12 vs. the industry median of 9.45, Vir Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.45, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vir Biotechnology's current PS Ratio of 5.16 is 45.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vir Biotechnology and its competitors. For the Biotechnology industry, the median PS Ratio is 9.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vir Biotechnology's current PS Ratio is 5.16, which is 78% below median its own 10-year median of 23.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current PS Ratio of 5.16. The stock's GF Value™ is MXN764.28, compared to a current price of MXN170.00 — trading 77.8% below its estimated fair value. The current PS Ratio is 5.16, which is 78% below median its 10-year median of 23.12 and 45.4% below the Biotechnology industry median of 9.45. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current PS Ratio is 5.16 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.8% below its estimated GF Value™ of MXN764.28.
Key valuation signals for MEX:VIR:
PS Ratio: 5.16 (78% below median its 10-year median of 23.12)
GF Value™: MXN764.28 vs. price of MXN170.00 (77.8% below fair value)
Industry Position: 45.4% below the Biotechnology median (#304 of 931)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
